Novartis (Switzerland) Insiders
| NOVN Stock | CHF 93.27 0.11 0.12% |
Novartis employs about 102 K people. The company is managed by 10 executives with a total tenure of roughly 238000 years, averaging almost 23800.0 years of service per executive, having 10200.0 employees per reported executive. Recap of Novartis' management performance can provide insight into the venture performance.
| Richard Saynor Insider Chief Sandoz |
| Steffen Lang Insider Pres Operations |
Novartis |
Novartis Management Team Effectiveness
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Novartis Workforce Comparison
Novartis AG is considered to be number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers—General industry is now estimated at about 624,195. Novartis retains roughly 102,000 in number of employees claiming about 16% of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.25 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.25. Novartis AG Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Novartis AG Price Series Summation is a cross summation of Novartis price series and its benchmark/peer.
Novartis Notable Stakeholders
A Novartis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novartis often face trade-offs trying to please all of them. Novartis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novartis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Richard Saynor | Chief Sandoz | Profile | |
| Steffen Lang | Pres Operations | Profile | |
| MarieFrance Tschudin | Pres Officer | Profile | |
| Paul Penepent | Head Accounting | Profile | |
| Samir MD | Global Relations | Profile | |
| Robert PharmD | Chief Officer | Profile | |
| Klaus Moosmayer | Risk Ethics | Profile | |
| Karen Hale | Chief Officer | Profile | |
| Vasant Narasimhan | Chief Officer | Profile | |
| Harry Kirsch | Chief Officer | Profile |
About Novartis Management Performance
The success or failure of an entity such as Novartis AG often depends on how effective the management is. Novartis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novartis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novartis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. NOVARTIS N operates under Drug ManufacturersGeneral classification in Switzerland and is traded on Switzerland Exchange. It employs 108000 people.
Please note, the imprecision that can be found in Novartis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novartis AG. Check Novartis' Beneish M Score to see the likelihood of Novartis' management manipulating its earnings.
Novartis Workforce Analysis
Traditionally, organizations such as Novartis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novartis within its industry.Novartis Manpower Efficiency
Return on Novartis Manpower
| Revenue Per Employee | 508.1K | |
| Revenue Per Executive | 5.2B | |
| Net Income Per Employee | 68.2K | |
| Net Income Per Executive | 695.5M |
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.